About Thoratec (NASDAQ:THOR)
Thoratec Corporation develops, manufactures and markets medical devices used for mechanical circulatory support for the treatment of heart failure patients. The Company's products include ventricular assist devices (VADs), such as HeartMate II Left Ventricular Assist System (HeartMate II), HeartMate III Left Ventricular Assist System, Thoratec Paracorporeal Ventricular Assist Device (PVAD) and Thoratec Implantable Ventricular Assist Device (IVAD). For acute circulatory support, the Company's product lines are CentriMag Acute Circulatory System (CentriMag) and for pediatric patients PediMag/PediVAS Acute Circulatory System (PediMag/PediVAS). HeartMate III, a centrifugal-flow, chronic, left ventricular assist system.
Industry, Sector and Symbol
Sub-IndustryHealth Care Equipment
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
EPS (Most Recent Fiscal Year)N/A
Return on Equity8.02%
Return on Assets6.71%
Thoratec (NASDAQ:THOR) Frequently Asked Questions
What is Thoratec's stock symbol?
Thoratec trades on the NASDAQ under the ticker symbol "THOR."
How were Thoratec's earnings last quarter?
Thoratec Co. (NASDAQ:THOR) announced its quarterly earnings results on Tuesday, August, 4th. The medical instruments supplier reported $0.37 earnings per share for the quarter, beating analysts' consensus estimates of $0.28 by $0.09. The medical instruments supplier earned $128.70 million during the quarter, compared to analysts' expectations of $115.48 million. Thoratec had a net margin of 10.29% and a return on equity of 8.02%. Thoratec's quarterly revenue was up 9.0% compared to the same quarter last year. During the same period in the previous year, the company earned $0.43 earnings per share. View Thoratec's Earnings History.
Has Thoratec been receiving favorable news coverage?
Headlines about THOR stock have trended somewhat positive on Wednesday, according to Accern Sentiment. The research group identifies negative and positive media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Thoratec earned a media sentiment score of 0.10 on Accern's scale. They also gave news coverage about the medical instruments supplier an impact score of 44.95 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near term.
How do I buy shares of Thoratec?
Shares of THOR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How can I contact Thoratec?
Thoratec's mailing address is 6035 Stoneridge Dr, PLEASANTON, CA 94588, United States. The medical instruments supplier can be reached via phone at +1-925-8478600.
MarketBeat Community Rating for Thoratec (THOR)MarketBeat's community ratings are surveys of what our community members think about Thoratec and other stocks. Vote "Outperform" if you believe THOR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe THOR will underperform the S&P 500 over the long term. You may vote once every thirty days.
Thoratec (NASDAQ:THOR) Analyst Ratings History
(Data available from 4/25/2016 forward)
|Date||Brokerage||Action||Rating||Price Target||Impact on Share Price||Details|
Thoratec (NASDAQ:THOR) Earnings History and Estimates Chart
Thoratec (NASDAQ THOR) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|8/4/2015||Q215||$0.28||$0.37||$115.48 million||$128.70 million||View||Listen|
|5/7/2015||Q115||$0.26||$0.38||$111.10 million||$121.31 million||View||Listen|
|2/10/2015||Q414||$0.24||$0.39||$106.90 million||$127.96 million||View||Listen|
|11/5/2014||Q314||$0.22||$0.18||$106.30 million||$105.80 million||View||Listen|
|8/6/2014||Q214||$0.43||$0.43||$128.30 million||$118.10 million||View||Listen|
|5/6/2014||Q114||$0.39||$0.41||$122.56 million||$125.70 million||View||Listen|
|2/4/2014||Q413||$0.41||$0.38||$128.47 million||$128.20 million||View||Listen|
|10/30/2013||Q313||$0.40||$0.49||$121.25 million||$126.40 million||View||Listen|
|7/31/2013||Q2 2013||$0.43||$0.52||$121.51 million||$130.50 million||View||Listen|
|5/2/2013||Q1 2013||$0.46||$0.41||$122.53 million||$117.73 million||View||Listen|
|2/5/2013||Q4 2012||$0.38||$0.38||$119.09 million||$128.50 million||View||Listen|
|11/1/2012||Q312||$0.39||$0.41||$111.80 million||$117.80 million||View||N/A|
Thoratec (NASDAQ:THOR) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Thoratec (NASDAQ THOR) Insider Trading and Institutional Ownership History
Thoratec (NASDAQ THOR) Insider Trading History
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|5/26/2015||Neil F Dimick||Director||Sell||8,173||$44.98||$367,621.54|| |
|5/15/2015||Paul A Laviolette||Director||Sell||5,668||$44.70||$253,359.60|| |
|4/10/2015||Neil F Dimick||Director||Sell||4,786||$43.00||$205,798.00|| |
|12/4/2014||J Daniel Cole||Director||Sell||5,000||$31.83||$159,150.00|| |
|5/27/2014||Neil F Dimick||Director||Sell||4,158||$32.15||$133,679.70|| |
|5/15/2014||Paul Laviolette||Director||Sell||6,023||$31.23||$188,098.29||19,299|| |
|3/10/2014||Gerhard Burbach||CEO||Sell||22,104||$36.53||$807,459.12||128,324|| |
|2/11/2014||Gerhard Burbach||CEO||Sell||20,000||$34.71||$694,200.00||156,307|| |
|1/15/2014||Gerhard Burbach||CEO||Sell||9,400||$38.10||$358,140.00||156,307|| |
|1/14/2014||Gerhard Burbach||CEO||Sell||30,600||$36.65||$1,121,490.00||156,307|| |
|12/10/2013||Gerhard Burbach||CEO||Sell||40,000||$38.15||$1,526,000.00||156,307|| |
|11/12/2013||Gerhard Burbach||CEO||Sell||100,000||$41.40||$4,140,000.00||156,307|| |
|10/28/2013||Gerhard F Burbach||CEO||Sell||15,000||$40.02||$600,300.00|| |
|10/17/2013||Gerhard F Burbach||CEO||Sell||9,600||$39.00||$374,400.00|| |
|10/14/2013||Gerhard Burbach||CEO||Sell||40,400||$38.17||$1,542,068.00||156,307|| |
|10/11/2013||David Aaron Lehman||SVP||Sell||21,889||$38.17||$835,503.13||43,077|| |
|5/28/2013||Neil F Dimick||Director||Sell||1,273||$31.58||$40,201.34|| |
|5/20/2013||Neil F Dimick||Director||Sell||1,250||$31.61||$39,512.50|| |
|5/13/2013||Neil F Dimick||Director||Sell||1,250||$33.93||$42,412.50|| |
|11/26/2012||Gerhard F Burbach||CEO||Sell||11,600||$38.09||$441,844.00|| |
|10/4/2012||David Aaron Lehman||SVP||Sell||12,300||$36.11||$444,153.00|| |
Thoratec (NASDAQ THOR) News Headlines
Thoratec (NASDAQ:THOR) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Thoratec (NASDAQ:THOR) Income Statement, Balance Sheet and Cash Flow Statement
Thoratec (NASDAQ THOR) Stock Chart for Wednesday, April, 25, 2018